Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

Sandra Jernström,1,2 Vesa Hongisto,3 Suvi-Katri Leivonen,1,2 Eldri Undlien Due,1 Dagim Shiferaw Tadele,1 Henrik Edgren,4,5 Olli Kallioniemi,4 Merja Perälä,6 Gunhild Mari Mælandsmo,2,7,8 Kristine Kleivi Sahlberg,1,9 1Department of Cancer Genetics, Institute for Ca...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK
Format: article
Langue:EN
Publié: Dove Medical Press 2017
Sujets:
ERBB2
drug screening
gene expression
pharmacogenomics
predictors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/5242fb84bf7e40c0a4884802397f2a64
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/5242fb84bf7e40c0a4884802397f2a64

Documents similaires